Fact based stock research
Sanofi (ENXTPA:SAN)

FR0000120578

Sanofi stock research in summary

sanofi.com


Sanofi shares are less expensive than other comparable stocks. While they are good value, they are riskily financed, and show below average growth. We recommend evaluating whether the future of the company Sanofi is really as difficult as the low price of the stock suggests. If you believe that the future of the company is market-typical or even better, then this could be an argument for a share purchase.


Latest Obermatt Ranks


Country France
Industry Pharmaceuticals
Index CAC All, CAC 40, NASDAQ, SBF 120, EURO STOXX 50
Size class XX-Large

September 3, 2021. Stock data may be delayed. Login to get the most recent research.


Achievements

Stock Discussion

Top 10 Stock


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Sanofi from September 3, 2021.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.